Noninfectious immune-mediated uveitis and ocular inflammation

Current Allergy and Asthma Reports

Volumn 14, Issue 1, 2014, Pages

  Pan, Jennifer ^a   Kapur, Manuj ^b   McCallum, Rex ^b  

^a USA   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Corticosteroid; HLA B27; Immunomodulatory therapy; Iritis; Ocular inflammation; Panuveitis; Pars planitis; Posterior uveitis; Steroid implant; Systemic disease; Uveitis

Indexed keywords

ARTHRITIS, JUVENILE; BEHCET SYNDROME; COMORBIDITY; HUMAN; IMMUNOLOGY; INFLAMMATION; OPHTHALMIA, SYMPATHETIC; SPONDYLARTHROPATHIES; UVEITIS; UVEOMENINGOENCEPHALITIC SYNDROME; BEHCET DISEASE; JUVENILE RHEUMATOID ARTHRITIS; MENINGOENCEPHALITIS; REVIEW; SPONDYLOARTHROPATHY; SYMPATHETIC OPHTHALMIA;

ARTHRITIS, JUVENILE; BEHCET SYNDROME; COMORBIDITY; HUMANS; INFLAMMATION; OPHTHALMIA, SYMPATHETIC; SPONDYLARTHROPATHIES; UVEITIS; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 84894371526     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-013-0409-1     Document Type: Article

References (58)

1. Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment (MUST) Trial. Ophthalmology. 2011;118:1916-26.
2. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332-6.
3. Chang JH, McCluskey PJ, Fracs F, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol. 2005;50:364-88.
4. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature (SUN) for reporting clinical data. -Results of the First International Workshop. Am J Ophthalmol. 2005;150:509-16.
5. D'Alessandro LP, Forster DJ, Rao NA. Anterior uveitis and hypopyon. Am J Ophthalmol. 1991;112(3):317-21.
6. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol. 1997;115:61.
7. Paiva ES, Macaluso DC, Edwards A, Rosenbaum JT. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis. 2000;59:67.
8. Bayen H, Bayen MC, De Curzon HP, et al. Involvement of the posterior eye segment in HLA B27 (+) iridocyclitis. J Fr Ophthalmol. 1988;11:561-6.
9. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15-25.
10. Leak AM, Ansell BM, Burman SJ. Antinuclear antibody studies in juvenile chronic arthritis. Arch Dis Child. 1986;61:168-72.
11. Kotaniemi K, Savolainen A, Karma A, Aho K. Recent advances in uveitis of juvenile idiopathic arthritis. Surv Ophthalmol. 2003;48(5):489-502.
12. Gregory 2nd AC, Kempen JH, Daniel E, Kacmaz RO, Foster CS, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120:186-92.
13. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics. 2006; 117(5):1843-1845.
14. Southward TR, Ryder CA. Ophthalmological screening in juvenile arthritis: should the frequency of screening be based on the risk of developing chronic iridocyclitis? Br J Rheumatol. 1992;31:633-4.
15. Henderly DE, Haymond RS, Rao NA, Smith RE. The significance of the pars plana exudates in pars planitis. Am J Ophthalmol. 1987;103:669-71.
16. David JI, Mittal KK, Nussenblatt RB. HLA in intermediate uveitis. Dev Ophthalmol. 1992;23:35-7.
17. Zein G, Berta A, Foster CS. Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm. 2004;12:137.
18. Prieto JF, Dios E, Gutierrez JM, et al. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflamm. 2001;9:93.
19. Obenauf CD, Shaw HE, Sydnor CF, Klintworth GK. Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol. 1978;86:648.
20. James DG. Ocular sarcoidosis. Ann N Y Acad Sci. 1986;465:551.
21. Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol. 1986;102:297-301.
22. Hegab S, Al-Mutawa S. Immunopathogenesis of Behcet's disease. Clin Immunol. 2000;96:174-86.
23. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990;335:1078.
24. Mamo JG. The rate of visual loss in Behçet's disease. Arch Ophthalmol. 1970;84:451.
25. Atmaca LS. Fundus changes associated with Behçet's disease. Graefe's Arch Clin Exp Ophthalmol. 1989;227:340-4.
26. Masuda K, Inaba G, Mizushima II. A nationwide survey of Behcet's disease in Japan. Jpn J Ophthalmol. 1974;19:278-85.
27. Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behçet's Disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130(5):592-8.
28. Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109:682.
29. Zhang XY, Wang XM, Hu TS. Profiling human leukocyte antigens in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1992;113:567.
30. Snyder DA, Tessler HH. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1980;90:69-75.
31. Moorthy RS, Inomata H, Rao NAL. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39:265-92.
32. Duke-Elder S, Perkins ES. Sympathetic ophthalmitis, in Duke-Elder S: Diseases of the uveal tract. Mosby: St Louis; 1966. p. 558-93.
33. Rao NA, Forster DJ, Spalton DJ. Sympathetic ophthalmia. In: Podos SM, Yanoff M, editors. The uvea uveitis and intraocular neoplasms, vol. 2. USA: Mosby-Wolfe; 1995. p. 8.10-3. Chapter 8.
34. Kilmartin DJ, Dick AD, Forrester JV. Prospective surveillance of sympathetic ophthalmia in the UK and Republic of Ireland. Br J Ophthalmol. 2000;84:259-63.
35. Watzke RC, Packer AJ, Folk JC, et al. Punctate inner choroidopathy. Am J Ophthalmol. 1984;98:572-84.
36. Schlaegel Jr TF. Eye histoplasmosis. Ann Ophthalmol. 1979;11:1645-54.
37. Gass JD. Acute posterior multifocal placoid pigment epitheliopathy. Arch Ophthalmol. 1968;80:177-85.
38. Sinan C, Thierry V, Jeffrey SR, Neil AB. Neurological manifestations of acute posterior multifocal placoid pigment epitheliopathy. Stroke. 1996;27:996-1001.
39. O'Halloran HS, Berger JR, Lee WB, et al. Acute multifocal placoid pigment epitheliopathy and central nervous system involvement. Nine new cases and a review of the literature. Ophthalmology. 2001;108:861-8.
40. Palestine AG, Nussenblatt RB, Chan CC, et al. Histopathology of the subretinal fibrosis and uveitis syndrome. Ophthalmology. 1985;92:838-44.
41. LeHoang P, Ozdemir N, Benhamou A, et al. HLA-A29.2 subtype associated with birdshot retinochoroidopathy. Am J Ophthalmol. 1992;113:33.
42. Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol. 2011;56(6):474-510.
43. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492.
44. Miserocchi E, Modorati G, Foster CS. New treatments in noninfectious uveitis. Dev Ophthalmol Basel, Karger. 2012;51:1-6.
45. Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology. 2011;50:1390-4.
46. Foster CS, Vitale AT. Immunosuppressive chemotherapy. In: Foster CS, Vitale AT, editors. Diagnosis and treatment of uveitis. 1st ed. Philadelphia, PA: WB Saunders; 2002. p. 177-214.
47. Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148:500-9.
48. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115:1416-21.
49. Fauc AS, Doppman JL, Wolff SM. Cyclophosphamide-induced remissions in advanced polyarteritis nodosa. Am J Med. 1978;64:890-4.
50. Fosdick WM, Parsons JL, Hill DF. Long-term cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum. 1968;11:151-61.
51. Martin-Suarez I, D'Cruz D, Mansoor M, et al. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rhem Dis. 1997;56:481-7.
52. Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117:576-84.
53. Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123:634-41.
54. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52:2447.
55. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903.
56. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:2480.
57. Okada AA, Goto H, Ohno S, Mochizuki M. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 2012;13:592-8.
58. Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11(1):35-9.